ReviewInternational journal of molecular sciences2017
The Molecular and Phenotypic Basis of the Glioma Invasive Perivascular Niche.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- The Invasive Margin of Glioblastoma as a Molecular Ecosystem: Spatial Heterogeneity, Tumor-Host Interactions, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- How is rosette formation in brain tumours linked with cerebrospinal fluid spread?Brain tumor pathology · 2026Review
- Localized treatment of glioblastoma: a review of clinical strategies and advances in drug delivery systems.Nanomedicine (London, England) · 2025Review
- A Murine Model of Glioblastoma Initiating Cells and Human Brain Organoid Xenograft for Photodynamic Therapy Testing.International journal of molecular sciences · 2025Article
- Article
- Peritumoral brain zone in glioblastoma: biological, clinical and mechanical features.Frontiers in immunology · 2024Review
- hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560.PloS one · 2024Article
- Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.Antioxidants & redox signaling · 2023Review
- Imaging glymphatic response to glioblastoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy.Cells · 2023Article
- Investigating the Interactions of Glioma Stem Cells in the Perivascular Niche at Single-Cell Resolution using a Microfluidic Tumor Microenvironment Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Glioma: molecular signature and crossroads with tumor microenvironment.Cancer metastasis reviews · 2022Review
- Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives.Cancers · 2022Review
- The Roles of FHL3 in Cancer.Frontiers in oncology · 2022Review
- MICAL2 Promotes Proliferation and Migration of Glioblastoma Cells Through TGF-β/p-Smad2/EMT-Like Signaling Pathway.Frontiers in oncology · 2021Article
- A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas.Frontiers in oncology · 2021Review
- Review
- Conventional Treatment of Glioblastoma Reveals Persistent CD44Molecular neurobiology · 2020Article
- Engineered Hydrogels for Brain Tumor Culture and Therapy.Bio-design and manufacturing · 2020Article
- Voltage-gated ion channels mediate the electrotaxis of glioblastoma cells in a hybrid PMMA/PDMS microdevice.APL bioengineering · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are devastating brain cancers that have poor prognostic outcomes for their patients. Short overall patient survival is due to a lack of durable, efficacious treatment options. Such therapeutic difficulties exist, in part, due to several glioma survival adaptations and mechanisms, which allow glioma cells to repurpose paracrine signalling pathways and ion channels within discreet microenvironments. These Darwinian adaptations facilitate invasion into brain parenchyma and perivascular space or promote evasion from anti-cancer defence mechanisms. Ultimately, this culminates in glioma repopulation and migration at distances beyond the original tumour site, which is a considerable obstacle for effective treatment. After an era of failed phase II trials targeting individual signalling pathways, coupled to our increasing knowledge of glioma sub-clonal divergence, combinatorial therapeutic approaches which target multiple molecular pathways and mechanisms will be necessary for better treatment outcomes in treating malignant gliomas. Furthermore, next-generation therapy which focuses on infiltrative tumour phenotypes and disruption of the vascular and perivascular microenvironments harbouring residual disease cells offers optimism for the localised control of malignant gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.